COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03744910
Previous Study | Return to List | Next Study

Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline (IMAGINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03744910
Recruitment Status : Recruiting
First Posted : November 19, 2018
Last Update Posted : July 8, 2020
ICON Clinical Research
Information provided by (Responsible Party):
CSL Behring

Brief Summary:
This trial investigates whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.

Condition or disease Intervention/treatment Phase
Antibody-mediated Rejection Biological: Clazakizumab Drug: Normal saline Phase 3

Detailed Description:
This multi-center, randomized, double-blind, parallel-group, placebo-controlled, Phase 3 trial investigates whether clazakizumab may be beneficial for the treatment of CABMR in kidney transplant recipients by inhibiting the production of DSA and re-shaping T cell alloimmune responses. Subjects will be administered clazakizumab at a target dose of 12.5 mg (or placebo) by SC injection, Q4W for up to 260 weeks (or until graft loss or death). This "event driven" trial has been designed to evaluate the benefits of clazakizumab in prolonging the time to an all-cause composite allograft loss endpoint (primary endpoint) in patients with CABMR.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Actual Study Start Date : October 14, 2019
Estimated Primary Completion Date : January 2028
Estimated Study Completion Date : April 2028

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Clazakizumab
350 subjects will have a 50/50 chance of being randomly assigned to receive a 12.5 mg subcutaneous (SC) injection once every 4 weeks (Q4W). 175 subjects will be treated with clazakizumab for up to 260 weeks.
Biological: Clazakizumab
Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Placebo Comparator: Placebo
350 subjects will have a 50/50 chance of being randomly assigned to receive a SC injection of normal saline once every 4 weeks (Q4W). 175 subjects will be treated with normal saline for up to 260 weeks.
Drug: Normal saline
Normal saline

Primary Outcome Measures :
  1. Incidence of all cause composite allograft loss [ Time Frame: Five years ]
    The aim of this study is to follow enrolled participants until 221 occurrences of all-cause allograft loss, defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR <15 mL/min/1.73 m2 or death from any cause have been observed. The analysis will be a stratified log rank test of the effect of treatment on all-cause composite allograft loss, with stratification factors of dichotomized baseline eGFR (25-45 mL/min/1.73 m2 versus >45-65 mL/min/1.73 m2), baseline proteinuria, treatment for early (within 6 months of transplant) ABMR rejection episodes (yes/no), and treatment for late (greater than 6 months post transplant) ABMR rejection episodes (yes/no). Surviving subjects without allograft loss will be censored at the time of their last assessment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Unless specified otherwise, all eligibility criteria time-intervals are assessed with respect to the screening visit. In order to be eligible to participate in the trial, a subject must meet all of the following inclusion criteria:

  1. Age 18-70 years.
  2. Living donor/deceased donor kidney transplant recipients ≥6 months from time of transplant.
  3. Diagnosis of CABMR (according to Banff 2015 diagnostic criteria) to include all of the following:

    • Biopsy-proven CABMR (i.e., chronic glomerulopathy (cg) >0) with/without C4d staining. Repeat biopsy to be performed if previous biopsy is not within 6 months (+3 weeks) of the start of the screening period. The local pathologist's diagnosis will be reviewed by a central pathologist to confirm eligibility for entry into the study. Subjects without evidence of chronic tissue injury on light microscopy but who have glomerular basement membrane double contours on electron microscopy (cg1a) are eligible.
    • Positive for HLA DSA (using single-antigen bead-based assays) post-transplant. Local laboratory DSA results will be reviewed by the central HLA reviewer to confirm eligibility for entry into the study. If presence of HLA DSA is confirmed within 6 months (+3 weeks) of the start of the screening period, the test does not need to be repeated for eligibility.
    • Note: Treatments for ABMR (including CABMR) or TCMR are not allowed within 3 months of the start of screening (see Exclusion Criterion 3). If subject has received one of these treatments at any time prior, a repeat biopsy and repeat DSA test must be performed after halting/completing treatment (to show continuing CABMR). At least 2 months ± 2 weeks should elapse from the end of treatment before the repeat biopsy and DSA test can be performed.
  4. Written informed consent obtained from subject (or legally acceptable representative) before any trial-related procedures.

Unless specified otherwise, all exclusion criteria time-intervals are assessed with respect to the screening visit. A subject is not eligible if any exclusion criteria are met:

  1. Participant is unable or unwilling to comply with study procedures in the opinion of the Investigator.
  2. Multi-organ transplant recipient or cell transplant (islet, bone marrow, stem cell) recipient. Note: recipients of multiple previous kidney transplants are allowed.
  3. Treatment for ABMR (including CABMR) or TCMR within 3 months of the start of screening.
  4. Received T cell depleting agents (e.g., alemtuzumab, anti-thymocyte globulin) within 3 months of the start of screening.
  5. Treatment with mTOR inhibitors within 4 weeks of the start of screening.
  6. Biopsy showing pure TCMR or advanced interstitial fibrosis (ci3), advanced tubular atrophy (ct3), vascular fibrous intimal thickening (cv3) or other significant causes of renal dysfunction (e.g., BKV nephropathy, glomerulonephritis).
  7. Impaired renal function due to disorders in the transplanted allograft (e.g., renal artery stenosis, hydronephrosis).
  8. eGFR <25 mL/min/1.73 m2 or >65 mL/min/1.73 m2 (MDRD4).
  9. Nephrotic range proteinuria defined as spot urine albumin creatinine ratio (UACR) ≥2,200 mg/g (≥220 mg/mmol). If spot UACR is above defined limits, repeat test on separate day to confirm ineligibility (or collect 24-hour urine to confirm nephrotic range proteinuria (≥3.0 g/day)).
  10. Pregnant, breastfeeding, or unwillingness to practice adequate contraception (i.e., a highly effective or acceptable method of contraception) during the study and for 5 months after last dose of investigational drug.
  11. History of anaphylaxis or known hypersensitivity to clazakizumab or to any constituent of the drug product.
  12. Abnormal LFTs (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin >1.5 x upper limit of normal) or other significant liver disease.
  13. History of active tuberculosis (TB).
  14. History of latent TB (e.g., positive QuantiFERON-TB test) without history of active TB unless subject has completed a full course of prophylactic treatment.
  15. History of human immunodeficiency virus (HIV) infection or positive for HIV.
  16. Seropositive for hepatitis B surface antigen (HBsAg).
  17. Hepatitis C virus (HCV) RNA positive.
  18. Known EBV mismatch (at time of transplant): donor seropositive, recipient seronegative.
  19. History of GI perforation; diverticular disease or diverticulitis (except if disease has been fully excised); or inflammatory bowel disease (except fully excised ulcerative colitis).
  20. Neutropenia (<1,000/mm3) or thrombocytopenia (<50,000/mm3).
  21. Active infections requiring systemic antimicrobial agents and unresolved prior to screening.
  22. History of or current invasive fungal infection or other opportunistic infection, including (but not limited to) the following: a nontuberculous mycobacterial infection, aspergillosis, pneumocystosis, and toxoplasmosis.
  23. Active viral infections such as BKV, CMV, or EBV based on polymerase chain reaction (PCR) testing. Active infection is defined as a test result ≥ lower limit of quantification (LLOQ).
  24. Current or recent (within 3 months) participation in an interventional trial.
  25. Administration of a live vaccine within 6 weeks of the start of screening, including but not limited to the following:

    • Adenovirus
    • Measles, mumps, and rubella
    • Oral polio
    • Oral typhoid
    • Rotavirus
    • Varicella zoster
    • Yellow fever
  26. History of alcohol or illicit substance (including marijuana) abuse.
  27. Present or previous (within 3 years) malignancy except for basal cell carcinoma, fully excised squamous cell carcinoma of the skin, or non-recurrent (within 5 years) cervical carcinoma in-situ.
  28. Presence of a condition or abnormality (i.e., clinically significant endocrine, autoimmune, metabolic, neurological, psychiatric/psychological, renal, GI, hepatic, and hematological or any other system abnormalities that are uncontrolled with standard treatment) that in the opinion of the Investigator would compromise the safety or life expectancy of the patient or the quality of the data.
  29. History of intolerance to trimethoprim and/or sulfamethoxazole. This criterion does not apply if subject is already taking another suitable Investigator-approved alternative for Pneumocystis jiroveci pneumonia (PJP) prophylaxis, or if subject is willing to begin taking an Investigator-approved alternative prophylactic therapy at least 1 week prior to the Day 1 Baseline visit (Visit 2).
  30. Prior exposure to clazakizumab, TCZ, or other IL-6/IL-6R blockers.
  31. ABO-incompatible transplant recipient.
  32. Severe hypogammaglobulinemia (defined as immunoglobulin G (IgG) <400 mg/dL).
  33. Prior (within 2 years of the start of screening) exposure to proteasome inhibitors (e.g., bortezomib).
  34. Active infection with COVID-19:

34a. Subject not known to have been previously infected with COVID-19 must have a negative PCR test during the screening period as near to the Day 1 Baseline visit (Visit 2) as possible. If subject is unwell with symptoms suggestive of COVID 19 disease but PCR test is negative, other causes for symptoms must be ruled out to determine subject eligibility.

34b. Subject known to have been previously infected with COVID-19 must meet all of the following conditions:

  • Must be asymptomatic for at least 1 month before the start of screening and have had 2 negative PCR tests at least 24 hours apart (either prior to or during screening) to confirm recovery.
  • Must be re-established on background immunosuppressants for at least 2 weeks prior to the start of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03744910

Layout table for location contacts
Contact: Head Project Management and Clinical Operations 844-448-2580
Contact: Head Regulatory Affairs 844-448-2580

Show Show 52 study locations
Sponsors and Collaborators
CSL Behring
ICON Clinical Research
Layout table for investigator information
Study Chair: Edward Chong, MBChB, MRCP CSL Behring
Layout table for additonal information
Responsible Party: CSL Behring Identifier: NCT03744910    
Other Study ID Numbers: CSL300_3001 (VKTX01)
First Posted: November 19, 2018    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CSL Behring:
Chronic Active
Antibody-mediated Rejection (AMR)